The Life Sciences IPOs + Capital Markets team advised the underwriters of Protara Therapeutics, Inc. (Nasdaq: TARA) two concurrent but separate public offerings of (i) 4,600,000 shares of its common stock and (ii) 4,148 shares of its non-voting Series 1 Convertible Preferred Stock. The public offering price of each share of common stock is $16.87 and the public offering price of each share of Series 1 preferred stock is $16,873.54. In addition, Protara has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the aggregate number of shares offered in the common stock offering. Protara expects to receive combined gross proceeds of $147.6 million from the offerings, before deducting underwriting discounts and offering expenses.
Protara is a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs.
The Goodwin team was led by Peter Rodas.
For more details, read the press release and article in Seeking Alpha.